This phase II trial studies how well contrast-enhanced ultrasound (CEUS) works for diagnosing patients with renal cell cancer (RCC) that has come back (recurrent) after an ablation. Diagnostic imaging, such as CEUS, may help find and monitor long term renal cell cancer recurrence following cryo or microwave ablation.
Additional locations may be listed on ClinicalTrials.gov for NCT05641935.
Locations matching your search criteria
United States
Pennsylvania
Philadelphia
Thomas Jefferson University HospitalStatus: Active
Contact: John Eisenbrey
Phone: 215-503-5188
PRIMARY OBJECTIVE:
I. To characterize and compare the sensitivity, specificity, positive and negative predictive value, and inter-reader agreement of two-dimensional (2D) CEUS and contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI) for detecting recurrent or residual RCC following ablation, using a combination of standard of care imaging follow-up and tissue pathology as a reference standard.
SECONDARY OBJECTIVES:
I. To evaluate the potential improvement to the qualitative assessments of 2D CEUS when fused with the patient’s pre-treatment cross sectional imaging.
II. To assess the potential added value of using multi-modality volumetric CEUS for detecting RCC recurrence post ablation.
III. To explore the use of quantitative imaging parameters extracted from 2D/three-dimensional (3D) CEUS datasets to determine if this improves the overall performance of CEUS.
EXPLORATORY OBJECTIVE:
I. An advanced Doppler technique designed for detection of slower flow will also be investigated as a non-contrast based approach for detecting recurrent disease.
OUTLINE:
Patients receive Lumason intravenously (IV) and undergo CEUS imaging with MRI/CT for approximately 1 hour on study. Patients' electronic medical record is reviewed every 6 months throughout study.
Upon completion of study intervention, patients are followed up at 30 days and then for up to 2 years.
Lead OrganizationThomas Jefferson University Hospital
Principal InvestigatorJohn Eisenbrey